Cited 16 time in
Platelet Reactivity and Clinical Outcomes After Drug-Eluting Stent Implantation: Results From the PTRG-DES Consortium
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Lee, S.-J. | - |
| dc.contributor.author | Cha, J.-J. | - |
| dc.contributor.author | Jeong, Y.-H. | - |
| dc.contributor.author | Hong, S.-J. | - |
| dc.contributor.author | Ahn, C.-M. | - |
| dc.contributor.author | Kim, J.-S. | - |
| dc.contributor.author | Ko, Y.-G. | - |
| dc.contributor.author | Choi, D. | - |
| dc.contributor.author | Hong, M.-K. | - |
| dc.contributor.author | Jang, Y. | - |
| dc.contributor.author | Joo, H.J. | - |
| dc.contributor.author | Chang, K. | - |
| dc.contributor.author | Park, Y. | - |
| dc.contributor.author | Song, Y.B. | - |
| dc.contributor.author | Ahn, S.G. | - |
| dc.contributor.author | Suh, J.-W. | - |
| dc.contributor.author | Lee, S.Y. | - |
| dc.contributor.author | Cho, J.R. | - |
| dc.contributor.author | Her, A.-Y. | - |
| dc.contributor.author | Kim, H.-S. | - |
| dc.contributor.author | Kim, M.H. | - |
| dc.contributor.author | Shin, E.-S. | - |
| dc.contributor.author | Lim, D.-S. | - |
| dc.contributor.author | Kim, B.-K. | - |
| dc.date.accessioned | 2023-01-04T05:35:01Z | - |
| dc.date.available | 2023-01-04T05:35:01Z | - |
| dc.date.issued | 2022-11 | - |
| dc.identifier.issn | 1936-8798 | - |
| dc.identifier.issn | 1876-7605 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/29930 | - |
| dc.description.abstract | Background: The long-term prognostic implication of platelet reactivity after percutaneous coronary intervention (PCI) is not clearly known. Objectives: The impacts of platelet reactivity from the PTRG-DES consortium were assessed. Methods: The primary endpoint was the major adverse cardiac and cerebrovascular events (MACCE) including all-cause death, myocardial infarction, stent thrombosis, or stroke. Key secondary endpoints were all-cause mortality, major bleeding, and net adverse clinical events (NACE), including MACCE and bleeding. Results: Between 2003 and 2018, a total of 11,714 patients were enrolled and grouped into tertiles according to P2Y12 reaction units (PRUs): high PRUs (≥253), intermediate PRUs (188-252), and low PRUs (<188). The Kaplan-Meier (KM) estimates of the primary outcome were significantly different across the groups; the high-PRU group showed the highest MACCE rate at 5 years (12.9%, 11.1%, and 7.0% in high-, intermediate-, and low-PRU groups, respectively; P < 0.001), as well as at 1 year (P < 0.001). The high-PRU group had the greatest KM estimates of all-cause death (8.2%, 5.9%, and 3.7%, respectively; P < 0.001) at 5 years without significant differences of major bleeding, and resultant of a higher KM estimates of NACE (15.7%, 13.6%, and 9.7%, respectively; P < 0.001). A PRU ≥252, the best cutoff value, was strongly related to MACCE (HR: 1.39; 95% CI: 1.11-1.74; P = 0.003) and all-cause death at 5 years after PCI (HR: 1.42; 95% CI: 1.04-1.94; P = 0.026). The optimal cutoff value of aspirin reaction units predicting the MACCE occurrence was ≥414 and was significantly associated with 5-year MACCE occurrence or all-cause death (P < 0.001). Conclusions: In this large-scale cohort, high PRU was significantly associated with occurrence of MACCE, all-death death, and NACE at 5 years, as well as 1 year after PCI. (PTRG-DES Consortium [PTRG]; NCT04734028) © 2022 American College of Cardiology Foundation | - |
| dc.format.extent | 13 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | Elsevier BV | - |
| dc.title | Platelet Reactivity and Clinical Outcomes After Drug-Eluting Stent Implantation: Results From the PTRG-DES Consortium | - |
| dc.type | Article | - |
| dc.publisher.location | 미국 | - |
| dc.identifier.doi | 10.1016/j.jcin.2022.09.007 | - |
| dc.identifier.scopusid | 2-s2.0-85141506898 | - |
| dc.identifier.wosid | 000893934900001 | - |
| dc.identifier.bibliographicCitation | JACC: Cardiovascular Interventions, v.15, no.22, pp 2253 - 2265 | - |
| dc.citation.title | JACC: Cardiovascular Interventions | - |
| dc.citation.volume | 15 | - |
| dc.citation.number | 22 | - |
| dc.citation.startPage | 2253 | - |
| dc.citation.endPage | 2265 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
| dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
| dc.subject.keywordPlus | PERCUTANEOUS CORONARY INTERVENTION | - |
| dc.subject.keywordPlus | ADJUST ANTIPLATELET THERAPY | - |
| dc.subject.keywordPlus | EAST-ASIAN PATIENTS | - |
| dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
| dc.subject.keywordPlus | OPEN-LABEL | - |
| dc.subject.keywordPlus | END-POINT | - |
| dc.subject.keywordPlus | CLOPIDOGREL | - |
| dc.subject.keywordPlus | ASPIRIN | - |
| dc.subject.keywordPlus | EVENTS | - |
| dc.subject.keywordPlus | DEFINITIONS | - |
| dc.subject.keywordAuthor | drug-eluting stent(s) | - |
| dc.subject.keywordAuthor | percutaneous coronary intervention | - |
| dc.subject.keywordAuthor | platelet function tests | - |
| dc.subject.keywordAuthor | stent thrombosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
